New microfluidic test could save preterm babies from deadly sepsis

This study tests a new microfluidic device that uses a very small blood sample (about half a teaspoon) to measure how well infection-fighting cells (neutrophils) work in premature babies. Sepsis is a major cause of death and long-term health problems in preterm infants, and current diagnosis is difficult. The goal is to see if this technology can predict which babies will develop sepsis and have worse outcomes, potentially leading to faster treatment and better care.